Stay updated on Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the information related to Pembrolizumab (MK-3475) as Maintenance Therapy in Treated Patients With Unresectable Stage III NSCLC.
    Difference
    0.1%
    Check dated 2024-06-06T14:28:53.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the clinical trial, specifying requirements such as age, health condition, and prior treatments. Previously, no information was provided regarding participation criteria.
    Difference
    40%
    Check dated 2024-05-22T21:19:24.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:14:23.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial page.